ライフサイエンスコーパス: AMP

1 AMP recoveries were higher than 98%, and RSD less than 7

2 AMP-activated kinase (AMPK) is a key player in energy se

3 AMP-activated protein kinase (AMPK) activation triggered

4 AMP-activated protein kinase (AMPK) and the homologous y

5 AMP-activated protein kinase (AMPK) is a key sensor and

6 AMP-activated protein kinase (AMPK) is a metabolic stres

7 AMP-activated protein kinase (AMPK) plays an essential r

8 AMP-related kinase (AMPK) is an important cellular energ

9 AMPs induce membrane permeability in E. coli spheroplast

10 t shared by the related purine metabolite 5'-AMP, inosine, or hypoxanthine.

11 f purified pol gamma was weak against the 5'-AMP-dRP block in a model BER substrate, and this activit

12 The ACMG/AMP guidelines recommend complete concordance of predict

13 clinically relevant variants using the ACMG/AMP guidelines.

14 These changes activate AMP activated protein kinase (AMPK), which in turn direc

15 he PKM1/2 knockdown in H1299 cells activated AMP-activated protein kinase (AMPK) signaling and stimul

16 e cellular starvation response and activates AMP-activated protein kinase (AMPK).

17 lin-dependent protein kinase beta, activates AMP-activated kinase (AMPK), leading to increased glucos

18 Glucose deprivation activates AMP-activated protein kinase (AMPK), but it is unclear w

19 ed treatment with DHA and Physcion activates AMP-activated protein kinase, leading to synergistic inh

20 Renal cortical concentrations of ATP, ADP, AMP, cAMP, creatinine phosphate and ATP:AMP ratio were i

21 idly after reperfusion and ratios of ATP/ADP/AMP after reperfusion are significantly correlated to gr

22 FA arrives at the airway, it rapidly adsorbs AMPs and creates negative complexes, thereby decreasing

23 chanism of killing for cationic, amphipathic AMPs, which may explain why most AMPs require micromolar

24 Broiler farms were 2.2 [ampicillin (AMP), p=0.017] to 23 [nalidixic acid (NX), p<0.001] time

25 y imprinted polymers (MIPs) with ampicillin (AMP) and to evaluate the feasibility of these materials

26 evates SIRT1 levels and activity in an AMPK (AMP-activated protein kinase alpha)-dependent manner.

27 RATIONALE: AMPK (AMP-activated protein kinase) is a heterotrimeric protei

28 ciency (IMD) and Toll pathway components, an AMP gene expression profile in Drosophila cells indicate

29 Here, we describe an AMP/ADP-independent mechanism that triggers AMPK activat

30 We show that the Nmrk2 gene is an AMP-activated protein kinase and peroxisome proliferator

31 of this study was to evaluate the role of an AMP-dependent kinase (AMPK) activator, 5-aminoimidazole-

32 ome by subtle structural modifications of an AMP.

33 turn governs autophagic response through an AMP-activated protein kinase (AMPK)-mediated feedforward

34 apacity of AMPK; features consistent with an AMP-induced myristoyl switch mechanism.

35 anx1) channels mediate the efflux of ATP and AMP from cancer cells in response to induction of extrin

36 r example, pyridoxal, folinic acid, ATP, and AMP) also convert the solution of 1 into a hydrogel.

37 ted by glucose-6-phosphate dehydrogenase and AMP kinase.

38 potential controls calcium homeostasis, and AMP-activated protein kinase (AMPK) is regulated, in par

39 key intermediates inosine monophosphate and AMP involved in the synthesis of ATP and GTP, prompting

40 nd increase in the hydrolysis of ATP/NAD and AMP, resulting primarily from the upregulation of pyroph

41 or glucose restriction (GR) regulate PKA and AMP-activated protein kinase (AMPK) to protect against D

42 background, cAMP/protein kinase A (PKA) and AMP-activated protein kinase (AMPK) signaling pathways a

43 val in CFA-exposed airway explants, ASL, and AMPs.

44 etabolites induced during treatment, such as AMP, reduce antibiotic efficacy and enhance phagocytic k

45 ribed the accumulation of extracellular ATP /AMP during chemotherapy-induced apoptosis in Jurkat huma

46 or cell death involves interplay between ATP/AMP efflux pathways and different cell-autonomous ectonu

47 The differences in extracellular ATP/AMP accumulation correlated with cell-line-specific expr

48 Robust extracellular ATP/AMP accumulation was observed in the FADD-deficient cell

49 Accumulation of extracellular ATP/AMP was similarly absent in RIP1-deficient Jurkat cells

50 leotidases that metabolized the released ATP/AMP.

51 Residues that contact the ATP/AMP in the MthRnl crystal structures are essential for t

52 3.17- and 2.12-fold increase in ATP:ADP, ATP:AMP and energy charge after portal venous reperfusion, r

53 ADP, AMP, cAMP, creatinine phosphate and ATP:AMP ratio were increased by diabetes and mostly decrease

54 tematic evaluation of ten publicly available AMP prediction methods.

55 ephropathy by regulating the liver kinase B1/AMP-activated protein kinase signaling pathway.

56 roscopy, and soft X-ray tomography that both AMPs and ampetoids trigger extensive and rapid non-speci

57 ng site, localized thanks to a protein-bound AMP molecule, a reaction product, is adjacent to the clu

58 recludes the allosteric activation of bGP by AMP.

59 ctivation of anaplerotic reactions driven by AMP deaminase 3 (Ampd3) and catabolism of branched-chain

60 ed aerobic glycolysis, a process mediated by AMP-activated protein kinase (AMPK) independently of HIF

61 teady-state membrane permeability induced by AMPs is quantitatively the same in spheroplasts and GUVs

62 lerated release and hydrolysis of ATP, cAMP, AMP, and NAD to adenosine.

63 Cationic AMPs bind negatively charged bacteria to exert their ant

64 Cationic AMPs typically exhibit an amphipathic conformation, whic

65 negative surface charge can adsorb cationic AMPs and form negative particle-protein complexes.

66 and mechanistic analogs of helical, cationic AMPs, which offer broad-spectrum antibacterial activity

67 s, pig and human ASL, and the human cationic AMPs beta-defensin-3, LL-37, and lysozyme to CFA or cont

68 the diverse mechanisms of action of cationic AMPs and the bacterial resistance against these peptides

69 to 6 functional groups, 1 of which, cationic AMPs, has received extensive attention in recent years f

70 However, certain AMPs instead appear to inhibit biomacromolecule synthesi

71 cGMP-AMP (cGAMP) synthase (cGAS) is a cytosolic DNA sensor th

72 In contrast AMP-activated protein kinase (AMPK) activation, which ca

73 This enzyme reversibly converts AMP, pyrophosphate, and phosphoenolpyruvate to ATP, orth

74 Cyclic AMP-response element-binding protein (CREB) plays key tr

75 Cyclic AMP-responsive element binding protein, hepatocyte speci

76 erculosis (Mtb) uses a complex 3', 5'-cyclic AMP (cAMP) signaling network to sense and respond to cha

77 rt failure based on its activity as a cyclic AMP booster.

78 vitro, and the cAMP analogue 8-bromo-cyclic AMP partially rescued the circadian phenotype in vivo We

79 E (HYPE) and filamentation-induced by cyclic AMP (FIC)-1, respectively-in Saccharomyces cerevisiae, a

80 Protein phosphorylation by cyclic AMP-dependent protein kinase (PKA) underlies key cellula

81 ft when h-channels are potentiated by cyclic AMP.

82 oxic moiety which increases host cell cyclic AMP (cAMP).

83 rdiomyocytes and smooth muscle cells, cyclic AMP (cAMP) and subsequent calcium (Ca(2+)) fluxes are th

84 d in the hippocampus that breaks down cyclic AMP and cyclic GMP.

85 uipotent with their parent peptide in cyclic AMP activation assays, but the GLP-1 thiopeptides have m

86 ving intracellular elements including cyclic AMP (cAMP).

87 When intracellular cyclic AMP (cAMP) levels rise, GluA2/3 channels shift to a high

88 IONALE: Although the second messenger cyclic AMP (cAMP) is physiologically beneficial in the heart, i

89 flux and ERK phosphorylation but not cyclic AMP production or CREB phosphorylation.

90 Inhibition of cyclic AMP (cAMP)-specific phosphodiesterase 4 (PDE4) has been

91 ctivity depends on cellular levels of cyclic AMP).

92 cyclase 5 catalyzes the production of cyclic AMP, which is a second messenger molecule involved in ce

93 gamma coactivator 1alpha (PGC1alpha), cyclic AMP-responsive element binding protein binding protein (

94 ic factor (BDNF)/TrkB and presynaptic cyclic AMP (cAMP)/PKA signaling.

95 eds of hormones and ligands stimulate cyclic AMP (cAMP) signaling in different tissues through the ac

96 d Som1, a downstream regulator of the cyclic AMP-dependent Protein Kinase A pathway.

97 response to histamine stimulation via cyclic AMP elevation.

98 nduction and increased phosphorylated cyclic-AMP response-binding protein (pCREB) to CREB ratio in th

99 y up-regulates production of keratin-derived AMPs (KAMPs) by the ubiquitin-proteasome system (UPS).

100 s reached, which was sufficient to determine AMP at levels allowed by the EU (4mugkg(-1)) in cow milk

101 PycA is inhibited by c-di-AMP and these mutations prompted us to examine the role

102 onal changes in the CT dimer induced by c-di-AMP binding may be the molecular mechanism for its inhib

103 esidues in the binding site can abolish c-di-AMP inhibition.

104 These data suggested that c-di-AMP modulates central metabolism at the pyruvate node to

105 Our earlier studies showed that c-di-AMP regulates central metabolism in Listeria monocytogen

106 yclic di-3',5'-adenosine monophosphate (c-di-AMP) is a broadly conserved bacterial second messenger t

107 Cyclic diadenosine monophosphate (c-di-AMP) is a conserved nucleotide second messenger critical

108 to L. monocytogenes via cyclic di-AMP (c-di-AMP), a secondary messenger molecule of L. monocytogenes

109 in L. lactis is negatively regulated by c-di-AMP, and high aspartate levels can be restored by expres

110 vels can be restored by expression of a c-di-AMP-insensitive LlPC.

111 r targets of L. monocytogenes-generated c-di-AMP.

112 hese bacterial enzymes are sensitive to c-di-AMP.

113 tion of Lactococcus lactis PC (LlPC) by c-di-AMP.

114 n response to L. monocytogenes via cyclic di-AMP (c-di-AMP), a secondary messenger molecule of L. mon

115 in biofilm-inducing medium lowers cyclic-di-AMP levels and does so in a manner that depends on the g

116 that degrades the second messenger cyclic-di-AMP, and xdrA, the gene for a transcription factor that,

117 diction tools show potential to discriminate AMPs from non-AMPs, but the relative quality of the pred

118 2,5Leu variant emerged as the most effective AMP during in vitro studies and was also highly effectiv

119 n, metabolic stress associated with elevated AMP/ATP ratio, and the intrinsic energy sensing capacity

120 idase (an enzyme that converts extracellular AMP to adenosine) develop spontaneous OA and chondrocyte

121 traction of the "effector loop" required for AMP binding releases the side chain of His23 from the di

122 nown site adjacent to the canonical site for AMP.

123 dontopathic biofilms is a challenge even for AMPs.

124 al agents and are consistent with a role for AMPs in mediating antimicrobial properties of the membra

125 nthobacter autotrophicus in the ligand-free, AMP-bound, and acetate coordinated states.

126 In the future, AMPs could be therapeutic tools for treatment of periodo

127 Among the six general AMP prediction tools-ADAM, CAMPR3(RF), CAMPR3(SVM), MLAM

128 ession of seven antimicrobial peptide genes (AMPs) after bacterial challenge.

129 DMXAA or the natural STING ligand cyclic GMP-AMP (cGAMP).

130 ich produces the second messenger cyclic GMP-AMP (cGAMP).

131 in the endosomal compartment and cyclic GMP-AMP synthase (cGAS) and absent in melanoma 2 (AIM2) in t

132 d cytokines through activation of cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (

133 ensing mechanism by targeting the cyclic GMP-AMP synthase (cGAS) and the stimulator of interferon (IF

134 lly, we determined that STING and cyclic GMP-AMP synthase (cGAS) are important to engage the type I I

135 e cofactor targets the DNA sensor cyclic GMP-AMP synthase (cGAS) for lysosomal degradation to avoid t

136 pression of the antiviral protein cyclic GMP-AMP synthase (cGAS) in neuronal SH-SY5Y cells, which is

137 immune therapies.Upon DNA binding cyclic GMP-AMP synthase (cGAS) produces a cyclic dinucleotide, whic

138 event autoimmunity; despite this, cyclic GMP-AMP synthase (cGAS), a cytosolic sensor of double-strand

139 Mice genetically deficient in cyclic GMP-AMP synthase (cGAS), its adaptor STING, IRF3, or the typ

140 though the cytosolic DNA receptor cyclic GMP-AMP synthase (cGAS), which produces the second messenger

141 mice) and caspase-1, and requires cyclic GMP-AMP synthase (cGAS)-dependent interferon-beta production

142 man monocytes binds and activates cyclic GMP-AMP synthase (cGAS).

143 rstanding the biological roles of cyclic GMP-AMP synthase and can serve as a molecular scaffold for d

144 ome demonstrate that ablating the cyclic GMP-AMP synthase gene abolishes the deleterious phenotype.

145 eport the discovery of a class of cyclic GMP-AMP synthase inhibitors identified by a high-throughput

146 Cyclic GMP-AMP synthase is essential for innate immunity against in

147 cytosolic DNA-sensing cGAS-STING (cyclic GMP-AMP synthase linked to stimulator of interferon genes) p

148 Upon binding double-stranded DNA, cyclic GMP-AMP synthase synthesizes a cyclic dinucleotide that init

149 ne of several upstream receptors, cyclic GMP-AMP synthase, binds to cytosolic DNA and generates dicyc

150 we present crystal structures of cyclic GMP-AMP synthase, double-stranded DNA, and inhibitors within

151 DNA substrate of TREX1 triggers a cyclic GMP-AMP synthase-dependent type I IFN response and systemic

152 d selective in cellular assays of cyclic GMP-AMP synthase-mediated signaling and reduces constitutive

153 DNA sensor proposed to act in the cyclic GMP-AMP synthase-stimulator of IFN genes pathway.

154 gely by chronic activation of the cyclic GMP-AMP synthase-stimulator of interferon genes-TANK-binding

155 Cyclic GMP-AMP synthetase (cGAS) is a DNA-specific cytosolic sensor

156 mtDNA was recognized by cyclic-GMP-AMP synthase (cGAS) in the DC cytosol, contributing to t

157 Hepatic AMP-activated protein kinase (AMPK) has been proposed to

158 ase) along with enzyme kinetic data show how AMP acts as an allosteric inhibitor and provides insight

159 irway epithelial cells better than the human AMP LL-37.

160 um bovis BCG, reveals significant changes in AMP and G6P levels during nutrient deprivation, which pr

161 this activation occurs solely via changes in AMP or ADP, the classical activators of AMPK.

162 e treated with IL-37 revealed an increase in AMP/ATP ratio, reduced levels of proinflammatory mediato

163 ate here that glucose deprivation results in AMP-activated protein kinase (AMPK)-mediated acetyl-CoA

164 vide evidence that soluble factors including AMPs are hCVAM antimicrobial agents and are consistent w

165 , and matrix protein synthesis by inhibiting AMP-activated protein kinase (AMPK) in renal cells.

166 Pase complexed with its allosteric inhibitor AMP shows an inactive form of the tetramer, in which the

167 Our results suggest that insect AMPs can be activated by Fkh factors under non-infectiou

168 during acute glucose starvation, and intact AMP-binding sites on AMPK are not required for AMPK acti

169 stimulation of a signaling cascade involving AMP-activated protein kinase, sirtuin 1, PGC-1alpha, sir

170 tant regulator of innate immunity, mediating AMP responses against both Gram-positive and Gram-negati

171 the signaling pathways of the CR mediators, AMP-activated protein kinase (AMPK) and sirtuin-1 are ac

172 in addition to acting at the cell membrane, AMPs may act on the cell wall, inhibit protein folding o

173 there is considerable interest in mimicking AMPs with stable, synthetic molecules.

174 eric regulators, adenosine 5'-monophosphate (AMP) and fructose 1,6-bisphosphate (FBP), respectively.

175 ves the addition of adenosine monophosphate (AMP) to a protein.

176 diphosphate (ADP), adenosine monophosphate (AMP), inosine monophosphate (IMP), inosine (Ino) and hyp

177 d PGC1alpha and low adenosine monophosphate (AMP)-activated kinase (AMPK) activity.

178 hosphate (ADP), and adenosine monophosphate (AMP); and antioxidants, the sum of oxidized and reduced

179 In general, most AMPs are thought to kill bacteria by binding to and disr

180 amphipathic AMPs, which may explain why most AMPs require micromolar concentrations for activity, sho

181 lin, mechanistic target of rapamycin (mTOR), AMP-activated protein kinase (AMPK), and autophagy pathw

182 In contrast to many natural AMPs, D-RR4 retained its activity under challenging phys

183 We compiled two sets of AMP and non-AMP peptides, separated into three categories-antimicrob

184 show potential to discriminate AMPs from non-AMPs, but the relative quality of the predictions produc

185 onas aeruginosa than the naturally-occurring AMP LL-37 in human plasma.

186 Activation of AMP-activated protein kinase (AMPK) by metformin, inhibi

187 oy receptor 8 (IL-1R8) and the activation of AMP-activated protein kinase (AMPK), because both inhibi

188 Activation of AMP-regulated protein kinase-retinoblastoma signaling is

189 nistically, SIRT2 maintained the activity of AMP-activated protein kinase (AMPK) in aged and Ang II-i

190 ective preconcentration and determination of AMP in cow milk samples.

191 the bursicon homodimers induce expression of AMP genes via Relish2 in Ae. aegypti, as prophylactic im

192 both pathways converging in the formation of AMP and adenosine via CD73.

193 Over the last decade, a number of AMP prediction tools have been designed and made freely

194 ere preceded by increased phosphorylation of AMP activated protein kinase (Ampk) at tyrosine 172 and

195 ed kinases, increased the phosphorylation of AMP-activated protein kinase, reduced intracellular pota

196 In contrast, only a narrow range of AMP concentrations permeabilized GUVs to a steady state.

197 mbranes are permeabilized by a wide range of AMP concentrations to the same steady-state membrane per

198 We compiled two sets of AMP and non-AMP peptides, separated into three categorie

199 The action of AMPs on spheroplasts is unique in producing an intracell

200 ension in GUVs also influences the action of AMPs, whereas the spheroplast membranes are tensionless.

201 know, this is the first time the actions of AMPs, on bacterial membranes and on model membranes, hav

202 ty of AMPs, the immunomodulatory activity of AMPs mediated by their interactions with host cells is i

203 In addition to the antimicrobial activity of AMPs, the immunomodulatory activity of AMPs mediated by

204 We also studied the adsorption of AMPs on PM.

205 thereby decreasing the functional amount of AMPs capable of killing pathogens.

206 hat end, we have characterized the attack of AMPs on Escherichia coli cytoplasmic membranes and direc

207 (GUVs) under well-defined concentrations of AMPs and fluorescent molecules.

208 m has now been introduced into the design of AMPs, minimizing the toxicity against mammalian cells wh

209 the first study investigating the effect of AMPs on airway-epithelia associated genes upon administr

210 Expression of AMPs is regulated mainly by NF-kappaB factors Dorsal, Di

211 ranes to study the molecular interactions of AMPs with bacterial membranes.

212 gy to enhance the therapeutic selectivity of AMPs.

213 tionic polypeptide, the helical structure of AMPs was distorted owing to the side-chain charge intera

214 Despite intense study of AMPs on model membranes, we do not know how well the mec

215 Indeed, the potential clinical use of AMPs has raised the concern that resistance to therapeut

216 ng in blood had almost no negative effect on AMP activity and even with 10% serum bacterial growth wa

217 ed the influence of r-bursicon homodimers on AMP production.

218 nal validation did not identify NF-kappaB or AMP-activated protein kinase phosphorylation, but uric a

219 Mechanistically, inhibiting VEGFR2 or AMP-activated protein kinase (AMPK), a major decorin-act

220 ntly, in contrast to what reported for other AMPs, the peptide was administered at 2 hours after bact

221 8c2,5Leu, alone or in combination with other AMPs, in the treatment of S. aureus intravenous catheter

222 effect but also clearly abolish the overall AMP-mediated stabilization effect in wild-type EcAGPase.

223 and the Association for Molecular Pathology (AMP) published updated standards and guidelines for the

224 (CAP), Association for Molecular Pathology (AMP), and the American Society of Clinical Oncology (ASC

225 the frog skin-derived antimicrobial peptide (AMP) Esc(1-21) and its diastereomer Esc(1-21)-1c were fo

226 a cells and increases antimicrobial peptide (AMP) gene expression, indicating immune pathway activati

227 The antimicrobial peptide (AMP) RNase 7 is constitutively expressed in the epidermi

228 cationic amphiphilic antimicrobial peptide (AMP) that is produced by cytotoxic T cells and natural k

229 p-regulation of five anti-microbial peptide (AMP) genes, noting the possibility that bursicon heterod

230 ic character of many antimicrobial peptides (AMP).

231 ontains antimicrobial proteins and peptides (AMPs).

232 Understanding how antimicrobial peptides (AMPs) and other membrane-active agents attack membranes

233 we demonstrate that antimicrobial peptides (AMPs) are an effective antibiofilm treatment when applie

234 Antimicrobial peptides (AMPs) are innate immune molecules that exhibit activitie

235 Antimicrobial peptides (AMPs) are naturally occurring peptides and promising can

236 ny organisms rely on antimicrobial peptides (AMPs) as a first line of defense against pathogens.

237 Antimicrobial peptides (AMPs) have shown rapid and potent effect against plankto

238 show that genes for antimicrobial peptides (AMPs) including human beta-defensins (HBDs) are expresse

239 The application of antimicrobial peptides (AMPs) is largely hindered by their non-specific toxicity

240 Antimicrobial peptides (AMPs) play an important role in defense against microbia

241 Antimicrobial peptides (AMPs) represent a promising therapeutic alternative for

242 sal epithelia deploy antimicrobial peptides (AMPs) to eliminate harmful microbes.

243 ericidal activity of antimicrobial peptides (AMPs).

244 We investigated PM-AMP electrostatic interaction by attenuated total reflec

245 coneogenesis, protein phosphatase 2A (PP2A), AMP-activated protein kinase (AMPK), and FoxO1 proteins.

246 ndings demonstrate its new role in producing AMPs for innate immune defense.

247 e beta-cell electrical activity by promoting AMP-activated protein kinase (AMPK)-dependent traffickin

248 than 40 antimicrobial peptides and proteins (AMPs) are expressed in the oral cavity.

249 egans larvae, the master metabolic regulator AMP-activated protein kinase (AMPK) plays a critical rol

250 ion of liver kinase B1 and the energy sensor AMP-activated protein kinase, as well as enhanced fatty

251 driven by activation of the metabolic sensor AMP kinase.

252 this study, we identify the metabolic sensor AMP-activated protein kinase (AMPK) as a beta1-integrin

253 ry functions have been published for several AMPs.

254 eutic advantage of this peptide over several AMPs.

255 ular ATP levels and concomitantly stimulated AMP-activated protein kinase in vitro and in vivo As an

256 LKB1, and its substrate, AMP-dependent protein kinase (AMPK) are important for HN

257 The activity of synthetic AMPs (Bac8c, HB43, P18, Omiganan, WMR, Ranalexin, and Po

258 We demonstrated that AMP-activated protein kinase (AMPK) modulates PXR transc

259 Recent studies demonstrated that AMP-activated protein kinase (AMPK) regulates neuronal m

260 tructural network analysis further show that AMP and G6P work synergistically as allosteric activator

261 Here, we showed that AMP-activated protein kinase (AMPK), the master metaboli

262 The AMP-activated protein kinase (AMPK) and the Gsk3 kinase

263 The AMP-activated protein kinase (AMPK) is a key regulator o

264 The AMP-activated protein kinase (SNF1 in yeast) is a centra

265 ack loop on protein kinase A mediated by the AMP-activated protein kinase Snf1 is coupled with a nega

266 nalized into osteoblasts were reduced by the AMP.

267 ntiation were not negatively affected by the AMP.

268 etabolism may have in chemotransduction; the AMP-activated protein kinase hypothesis and its current

269 Culturing the AMP-modifications with Escherichia coli, Enterococcus fa

270 ession of GOF mutant p53 G245D decreases the AMP-activated protein kinase (AMPK)-mediated phosphoryla

271 ingle point mutations of key residues in the AMP-binding site decrease its inhibitory effect but also

272 nstrate a high antimicrobial activity of the AMP even against bacteria incorporated in a biofilm or i

273 been recently proposed as activators of the AMP-activated protein kinase (AMPK) signaling pathway an

274 LKB1 in Tregs is largely independent of the AMP-activated protein kinase, but is mediated by the MAP

275 SLC13A5 depletion promotes activation of the AMP-activated protein kinase, which was accompanied by d

276 oliferation likely due to suppression of the AMP-regulated protein kinase-retinoblastoma axis with mi

277 RATIONALE: The AMP-activated protein kinase (AMPK) is stimulated by hyp

278 residues for FBP binding did not revert the AMP-mediated stabilization.

279 get of rapamycin pathways and stimulated the AMP-activated protein kinase pathway in both muscles.

280 mbryonic fibroblasts (MEFs) by targeting the AMP-activated protein kinase (AMPK).

281 Here, we demonstrate that the AMP-activated protein kinase (AMPK)-related protein Snf1

282 Here we report that the AMP-activated protein kinase alpha1 (AMPKalpha1) in mono

283 ether with the decreased charge density, the AMPs exhibited inhibited toxicity against mammalian cell

284 he cytotoxic and hemolytic activities of the AMPs against human cells and their immunomodulatory pote

285 At the infectious site, the AMPs can be activated by bacterial phosphatase to restor

286 d the concern that resistance to therapeutic AMPs could be associated with resistance to endogenous h

287 These AMP prediction tools show potential to discriminate AMPs

288 These AMPs have been organized into 6 functional groups, 1 of

289 This AMP was also able to reduce biofilm as demonstrated by F

290 We ascribed the effects of aspirin to AMP-activated protein kinase (AMPK) activation, mTORC1 i

291 r a CysRS from Borrelia burgdorferi bound to AMP, GluRS from Borrelia burgdorferi and Burkholderia th

292 nd finally, why development of resistance to AMPs is less prevalent than developed resistance to conv

293 Importantly, in some cell types AMP/ATP and ADP/ATP ratios remain unchanged during acute

294 at Mycobacterium tuberculosis (Mtb) PYK uses AMP and glucose-6-phosphate (G6P) as synergistic alloste

295 OGT regulates SREBP-1 protein expression via AMP-activated protein kinase (AMPK).

296 derstanding the molecular mechanism by which AMP and FBP allosterically modulates EcAGPase enzymatic

297 res suggest an allosteric mechanism in which AMP binding triggers a rearrangement of hydrogen bonds a

298 While AMPs should not cause widespread resistance due to their

299 the airways could potentially interact with AMPs in the ASL to affect their antimicrobial activity.

300 overed that Std1, the activator of the yeast AMP kinase Snf1, condensates into granules to tune Snf1